Alzheimer's News Today Home | Alzheimer's News Today
Nov 4, 2024 · Becoming educated and informed about Alzheimer’s is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
ALZ-801 for 2 years seen to sustain cognition in early Alzheimer’s
Sep 22, 2023 · ALZ-801 aims to work as a preventive therapy in early Alzheimer’s. Alzheimer’s is marked by the presence of beta-amyloid plaques and tau tangles, which are clumps of two proteins that build up to toxic levels inside brain nerve cells.
News Archives - Alzheimer's News Today
Alzheimer’s in people younger than 65 linked to night light exposure. Higher exposure to outdoor light at night may increase the risk of developing Alzheimer’s disease, especially in people younger than 65, according to a study that drew on Medicare records and …
Topline results of Phase 3 studies of simufilam for Alzheimer's...
Feb 8, 2024 · Simufilam is designed to target filamin A, a protein that forms abnormal clumps in Alzheimer’s and that’s also involved in amyloid-beta and tau clumping. By targeting filamin A, simufilam seeks to reduce brain damage and slow disease progression.
Modified Kisunla dosing lowers risk of ARIA-E in Alzheimer’s: Study
Nov 8, 2024 · Being started on a smaller dose of the approved early Alzheimer’s therapy Kisunla was found to reduce the risk of ARIA-E on imaging scans.
AAN 2023: ALZ-801 for Alzheimer's helps improve cognition in trial...
Apr 28, 2023 · The Phase 2 trial is assessing the safety and efficacy of daily ALZ-801 treatment for up to two years in 84 adults with early Alzheimer’s who have one or two copies of APOE4. Interim six-month results indicated that ALZ-801 safely lowered the levels of p-tau 181, a key biomarker of neurodegeneration, and led to significant memory improvements.
Muna, GSK partner to develop targets for Alzheimer's treatments
5 days ago · Muna will take the lead in identifying and validating new Alzheimer’s targets, while GSK will be responsible for the subsequent therapeutic development process, including preclinical studies, clinical trials, manufacturing, and commercialization, the companies said.
In early Alzheimer’s, Anavex 2-73 slows cognitive decline...
Sep 15, 2023 · In Alzheimer’s, the amyloid-beta protein forms toxic clumps that disrupt nerve cell function. A brain affected by Alzheimer’s is also marked by neuroinflammation, energy imbalances, and oxidative stress, a type of cellular damage.
About Us - Alzheimer's News Today
Alzheimer’s News Today is a digital platform intended to provide the Alzheimer’s disease community with the most recent news and information on the disease, as well as first-hand community perspectives from our patient and caregiver columnists.
What is Alzheimer's Disease? - Alzheimer's News Today
Jun 25, 2021 · Alzheimer’s disease is a progressive neurodegenerative disorder and the most common cause of dementia. It most often emerges during a person’s mid-60s or older, although early-onset varieties exist.
Skip to content